Nitazoxanide shows potential as a ferroptosis inducer in triple-negative breast cancer
Nitazoxanide, an FDA-approved drug, may be repurposed to induce ferroptosis in triple-negative breast cancer.
Asset / Drug
Drug and asset intelligence for Nitazoxanide with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.